The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Sulindac and polyp regression.
F M Giardiello (Profiled Author: Francis Giardiello)
Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287-4461, USA.
Cancer metastasis reviews 1994;13(3-4):279-83.
Sulindac is useful in regression of adenomatous polyps. In addition to orally administered sulindac, rectal preparations also appear to be efficacious . However, further studies are necessary to determine whether regression of adenomas, the precursor of colorectal cancer, will cause decrease in colorectal cancer risk in both FAP and non FAP patients. Moreover, clinical studies are needed to test the application of this potential chemopreventative drug in several other patient populations. Several interesting observations have been made concerning the use of sulindac. Indomethacin, a related NSAID to sulindac, did not cause polyp regression. Also, upper gastrointestinal tract polyps in the stomach and duodenum appear not to be affected by sulindac therapy. These observations might be explained by the metabolism of sulindac in which the pharmacologically active sulfide metabolite is generated and distributed in the large intestine. Also, investigators noted that after discontinuation of sulindac adenomas recurred. Sulindac treatment was well tolerated at the usual clinical doses. Although some investigators have speculated on the effect of prostaglandin inhibition sulindac on cAMP-dependent mechanisms which control cellular proliferation , the cause of adenoma regression is unknown. There is evidence that colorectal endogenous prostaglandin levels decrease with sulindac. Evaluation of colorectal mucosal cellular proliferation in patients treated with sulindac has revealed a decrease in labelling index by bromodeoxyuridine labeling in one study  but no change in labelling index by [3H]thymidine incorporation in another investigation . Also, ki 67 labelling index, another measure of cellular proliferation, was not affected in the colorectal mucosa of patients taking sulindac.(ABSTRACT TRUNCATED AT 250 WORDS)
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
F M Giardiello; J A Offerhaus; A C Tersmette; L M Hylind; A J Krush; J D Brensinger; S V Booker; S R HamiltonGut 1996;38(4):578-81.
R N DuBois; F M Giardiello; W E SmalleyGastroenterology clinics of North America 1996;25(4):773-91.
Y Beazer-Barclay; D B Levy; A R Moser; W F Dove; S R Hamilton; B Vogelstein; K W KinzlerCarcinogenesis 1996;17(8):1757-60.
Appears in this Publication
Author of this Publication